ATAI Life Sciences is advancing tabernanthaiboga (TBG), a synthetic ibogaine analog engineered to retain the drug's anti-addictive and neuroplasticity-promoting properties while eliminating — or dramatically reducing — the hallucinogenic effects and cardiac risks that have complicated ibogaine's clinical development. Early preclinical data are promising, and the compound represents one of the most closely watched next-generation ibogaine-adjacent programs in psychiatry and addiction medicine.

What Exactly Is Tabernanthaiboga?

Tabernanthaiboga (TBG) is a synthetic molecule based on the iboga alkaloid scaffold. It was developed from research led by David Olson's lab at UC Davis, which published influential findings in Cell Reports Medicine showing that TBG acts as a psychoplastogen — a compound that promotes rapid structural and functional neural plasticity — without producing the extended hallucinatory experience associated with ibogaine or 5-MeO-DMT.

In preclinical models, TBG demonstrated the ability to:

  • Reduce self-administration of alcohol, heroin, and cocaine in rodent models
  • Promote dendritic spine growth and synaptogenesis in prefrontal cortical neurons
  • Produce anti-depressant and anxiolytic effects in behavioral assays
  • Show a markedly reduced binding profile at sigma-2 receptors implicated in hallucination

The molecule is structurally derived from the iboga family but is not extracted from the Tabernanthe iboga plant — it is fully synthesized, which is critical for pharmaceutical-grade manufacturing and regulatory scalability.

How Does TBG Differ from Ibogaine?

Ibogaine's clinical development has faced two persistent obstacles: a prolonged, intense hallucinatory experience lasting 18–36 hours, and QTc interval prolongation that carries a risk of potentially fatal cardiac arrhythmias. These factors have kept ibogaine outside FDA approval even as patient demand and observational data have grown.

TBG was specifically designed to address both problems:

Property Ibogaine TBG (Preclinical)
Hallucinogenic duration 18–36 hours Significantly reduced in animal models
Cardiac (hERG channel) activity Substantial QTc risk Reduced hERG binding observed preclinically
Anti-addictive effect Strong clinical/observational evidence Positive preclinical signals
Neuroplasticity promotion Observed Observed — BDNF upregulation, spinogenesis
Regulatory status (US) Schedule I Not yet scheduled — IND-stage compound

It is important to note that preclinical reductions in cardiac liability and hallucinogenic activity do not automatically translate to humans. Human phase trials are necessary to confirm these properties.

Safety Note: TBG has not yet completed human clinical trials. Preclinical cardiac and hallucinogenic profiles, however encouraging, cannot be extrapolated with certainty to human responses. Neither TBG nor ibogaine should be self-administered. Ibogaine remains Schedule I in the United States, making possession and use illegal outside of FDA-authorized research contexts.

Where Does ATAI's TBG Program Currently Stand?

ATAI Life Sciences holds development rights to TBG through its portfolio company structure. The company's broader ibogaine-related strategy also includes DemeRx, which has been pursuing clinical development of ibogaine hydrochloride (IB) itself for opioid use disorder.

As of 2026, TBG remains in the preclinical-to-early-clinical transition phase. ATAI has disclosed IND (Investigational New Drug) application preparation activities and has signaled intent to advance TBG into Phase 1 human safety trials. The company's 2024 annual report cited TBG as a priority asset within its neuroplastogen pipeline, with particular focus on:

  • Opioid use disorder (OUD) — leveraging the anti-addictive mechanistic overlap with ibogaine
  • Treatment-resistant depression (TRD) — based on BDNF-mediated plasticity mechanisms
  • Alcohol use disorder (AUD) — supported by robust preclinical self-administration data

ATAI has also engaged with the FDA's Breakthrough Therapy Designation pathway for components of its ibogaine-related pipeline, though public confirmation of TBG-specific BTD status has not been announced as of publication. Researchers should monitor ClinicalTrials.gov and ATAI's investor communications for the most current trial registration information.

What Is the Proposed Mechanism Behind TBG's Effects?

The neurobiological rationale for TBG draws on converging lines of research into what makes ibogaine clinically interesting in the first place. Key mechanisms under study include:

  • GDNF and BDNF upregulation: Like ibogaine, TBG appears to promote glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) expression, which are thought to underlie synaptic remodeling in addiction circuits.
  • TrkB agonism pathway: Psychoplastogens including TBG may activate TrkB (the BDNF receptor) through mechanisms that overlap with ketamine and psilocybin but via a structurally distinct route.
  • Sigma receptor modulation: Ibogaine's sigma-2 receptor activity is believed to contribute to hallucination; TBG's reduced affinity at this receptor is a key design feature.
  • Opioid receptor interaction: Ibogaine's kappa and mu opioid receptor activity contributes to withdrawal suppression. Whether TBG preserves this pharmacology meaningfully in humans remains under investigation.

A 2021 Nature Medicine paper from the Olson group (Cameron et al.) provided foundational evidence that non-hallucinogenic psychoplastogens could promote stress resilience — a conceptual underpinning for the entire TBG development strategy.

What Are the Broader Implications for Ibogaine-Based Medicine?

TBG sits within a rapidly maturing field that includes multiple ibogaine analogs and derivatives. Parallel programs — including 18-methoxycoronaridine (18-MC), noribogaine, and various iboga-derived molecules — reflect a shared hypothesis: that the therapeutic core of ibogaine can be separated from its liabilities.

If TBG succeeds in Phase 1 and 2 trials, the implications would be substantial:

  • A cardiac-safe ibogaine analog could be administered in outpatient or less intensive monitored settings, dramatically expanding access
  • A non-hallucinogenic profile would remove the need for the extended supervised psychedelic experience, potentially reducing healthcare system burden
  • FDA approval of a Schedule I-adjacent compound would set regulatory precedent relevant to ibogaine itself
  • For the tens of millions of Americans with OUD, an effective new mechanism of action would represent a meaningful addition to buprenorphine and naltrexone-based care

Skeptics note that the hallucinogenic experience may itself be therapeutically relevant for some indications, and that stripping it away could reduce efficacy. This remains an open scientific question that clinical trials will be needed to resolve.

Frequently Asked Questions

No. TBG is a synthetic analog inspired by the iboga alkaloid scaffold but is a distinct chemical compound. It is not derived from the iboga plant and was specifically engineered to reduce the hallucinogenic and cardiac effects of ibogaine while attempting to preserve anti-addictive and neuroplasticity-promoting properties.
No. TBG is not approved by the FDA and is not available as a clinical treatment. It is currently in the preclinical-to-early-clinical development stage. Access would only be possible through a registered clinical trial. You can search ClinicalTrials.gov for any active TBG studies.
ATAI Life Sciences is a clinical-stage biopharmaceutical company that invests in and develops mental health and addiction treatments. Its ibogaine-related portfolio includes DemeRx (focused on ibogaine hydrochloride for OUD) and the TBG program. ATAI uses a portfolio model in which subsidiary companies advance individual assets through clinical development.
As of 2026, published peer-reviewed data on TBG in human subjects has not been released. ATAI has indicated IND preparation activities for Phase 1 trials. Published preclinical results originate primarily from David Olson's laboratory at UC Davis in rodent models.
ATAI has highlighted opioid use disorder, alcohol use disorder, and treatment-resistant depression as priority indications for TBG, based on the compound's preclinical profile. These align with the broader therapeutic areas where ibogaine has shown observational and early clinical promise.
Preclinical data suggest reduced hERG potassium channel binding compared to ibogaine, which is associated with lower QTc prolongation risk. However, human cardiac safety data do not yet exist. The cardiac safety profile of TBG in humans will be a primary endpoint of Phase 1 trials.
TBG is a novel synthetic compound and is not currently listed as a scheduled substance under the US Controlled Substances Act. However, ibogaine — the naturally occurring compound it is derived from conceptually — is Schedule I. Legal status of novel analogs can be complex and may be subject to analog act provisions or future scheduling. Consult a legal professional for specific guidance.
A psychoplastogen is a compound that rapidly promotes structural and functional plasticity in the brain — including dendritic spine growth, synaptogenesis, and neurotrophic factor expression. The term was coined by David Olson's group to describe a class of molecules that may produce lasting therapeutic effects through neural remodeling rather than solely through acute receptor activation. TBG, ibogaine, ketamine, and psilocybin all show psychoplastogenic properties to varying degrees.

Anyone researching TBG, ibogaine analogs, or ATAI's pipeline for personal treatment decisions should work directly with an addiction medicine specialist, psychiatrist, or clinical researcher familiar with the current trial landscape. For opioid use disorder specifically, evidence-based treatments including buprenorphine and naltrexone are currently FDA-approved and accessible — and should be discussed with a prescribing clinician while next-generation compounds like TBG complete their development pathway.

Informational only. Not medical or legal advice. Ibogaine is Schedule I in the US. Consult qualified professionals.